Demand for Pandemic Testing Could Rise Substantially with New Strain of Virus

The virus shows no signs of slowing. At the moment, there are 82.9 million cases of the virus. In the U.S., the case load is up to 19.7 million. Making matters worse, there’s now a new strain of the virus popping up in the UK. Colorado, and in California. In addition, according to Dr. Anthony Fauci, we could see reports from other states. “We predicted it would be, when you have so much of it in the UK, which then spread to other countries in Europe and Canada, it was inevitable that it would be here,” he said, as quoted by the New York Post. “You’ll be hearing reports from other states and more cases in the state that is already reported. Unfortunately, that’s just the reality of the way these viruses spread.” Worse, without quicker vaccine rollouts, the world could see spikes in cases, and possibly even lockdowns. Not only does the world need vaccines, it needs a good deal of testing. That’s where companies like Datametrex AI Limited (TSXV:DM)(OTC:DTMXF), Laboratory Corp. of America Holdings (NYSE:LH), Abbott Laboratories (NYSE:ABT), Quest Diagnostics Inc. (NYSE:DGX), and Chembio Diagnostics Inc. (NASDAQ:CEMI) come into play.

Datametrex AI Limited (TSXV:DM)(OTC:DTMXF) BREAKING NEWS: Datametrex AI Limited  is pleased to share that the Company’s Health Canada approved test kit, 1copy™ COVID-19 qPCR Multi Kit is capable of detecting the new strain of COVID-19 that is spreading rampantly throughout the United Kingdom and likely spreading globally as advised by the manufacturer through a report which the Company has received dated December 25, 2020 from the manufacturer.

The new mutated strain of COVID-19 as publicly reported is suggested to be 70% more infectious than the first strain.. Experts believe the new strain has very likely already made its way from the UK to Canada and the US. “This new mutated strain of COVID and its potential spread beyond the UK clearly demonstrates the importance of testing travelers. If testing was made mandatory before any travel was permitted, the globe would have a better chance of containing and preventing the spread of COVID-19” said Marshall Gunter, CEO of the Company.

“We believe that the best approach regulators should adopt is a process that tests the entire population, coupled with a track and trace protocol. This will enable the general population to return to a more normalized way of life, flatten the spread, and support vaccinations in effectively combatting the virus.”, said Andrew Ryu, Chairman of the Company.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

Other related developments from around the markets include:

Laboratory Corp. of America Holdings (NYSE:LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Walgreens announced that the Pixel by Labcorp At-Home COVID-19 Collection Kit is now available from Labcorp through Walgreens Find Care, a digital health platform available on the Walgreens app and Walgreens currently offers COVID-19 testing in more than 1,100 drive-thru locations across the country. “Labcorp and Walgreens share a common goal of helping customers find easy and safe ways to get COVID-19 test results and make informed health decisions,” said Amy Summy, executive vice president and chief marketing officer, Labcorp. “We’re excited to expand our collaboration and make our popular and easy-to-use Pixel by Labcorp At-Home COVID-19 Collection Kit available to even more customers.”

Abbott Laboratories (NYSE:ABT) announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for virtually guided at-home use of its BinaxNOW™ COVID-19 Ag Card rapid test for detection of COVID-19 infection. Abbott is bringing BinaxNOW, the most affordable and widely distributed rapid test into the home, where the result is delivered in minutes without the need to send it out for processing. The $25 cost for the test and service is the lowest currently available for at-home testing.   To facilitate the delivery of the BinaxNOW test to the home and the guided collection and testing process, Abbott has partnered with digital health solutions provider eMed. This agreement furthers Abbott's vision of making as many tests as possible available in a variety of different settings to improve accessibility, support consumer confidence in testing at home, and help people start returning to living their daily lives with more normalcy.

Quest Diagnostics Inc. (NYSE:DGX), the world's leading provider of diagnostic information services, and The Commons Project, a non-profit public trust dedicated to building and operating global digital platforms and services for public good, today announced a collaboration that will give individuals more control over how and when they can access their data. With the new collaboration, Quest Diagnostics also joins a handful of industry members of the Commons Project Foundation, which is focused on enabling people to access digital versions of their COVID-19 test results and vaccination records in order to more safely open international borders and resume economic activity. Through the new collaboration, individuals can elect to access their Quest Diagnostics laboratory testing data through CommonHealth, the privacy-preserving Android app. The solution makes it easier for patients to access and review all their health data on a single, secure app.

Chembio Diagnostics Inc. (NASDAQ:CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced the appointment of David Acheson, M.D. to the Company’s Board of Directors. “We are pleased to welcome David to our Board of Directors. He adds directly applicable expertise in public health and infectious disease management to our leadership team, and we are confident his perspective will contribute meaningfully to our long-term value creation strategy,” said Katherine L. Davis, Chair of Chembio's Board of Directors.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for Datametrex AI Limited by a third party. We own ZERO shares of Datametrex AI Limited. Please click here for full disclaimer.

Contact Information:
[email protected]